The use of post-translationally modified peptides for detection of biomarkers of immune-mediated diseases

Journal of Peptide Science

Volumn 15, Issue 10, 2009, Pages 621-628

  Papini, Anna Maria ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Autoantibodies; Autoimmune diseases; Neo antigens; Peptide antigenic probes; Post translational modifications

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; GLYCOPEPTIDE; SYNTHETIC PEPTIDE;

AMINO ACID SEQUENCE; ANTIBODY DETECTION; ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; MEDICAL DECISION MAKING; MOLECULAR INTERACTION; MOLECULAR PROBE; MULTIPLE SCLEROSIS; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN MICROARRAY; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; BIOLOGICAL MARKERS; CITRULLINE; HUMANS; INTERMEDIATE FILAMENT PROTEINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTIPLE SCLEROSIS; MYELIN-ASSOCIATED GLYCOPROTEIN; PEPTIDE LIBRARY; PEPTIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 70449650528     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1166     Document Type: Review

References (41)

1. Roland P, Atkinson JA, Lesko LJ. Use of biomarkers from drug discovery through clinical practice. Clin. Pharmacol. Ther. 2003; 73: 284-291.
2. Baker M. In biomarker we trust? Nat. Biotechnol. 2005; 23: 297-304.
3. Bialynicki-Birula R. The 100th anniversary of Wassermann-Neisser-Bruck reaction. Clin. Dermatol. 2008; 26: 79-88.
4. Shoenfeld Y, Gershwin ME, Meroni PL. Autoantibodies. Elsevier: London, 2007.
5. Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. J. Clin. Invest. 2001; 108: 1417-1422.
6. Doyle HA, Mamula MJ. Post-translational protein modifications in antigen recognition and autoimmunity. Trends Immunol. 2001; 22: 443-449.
7. Alcaro MC, Lolli F, Migliorini P, Chelli M, Rovero P, Papini AM. Peptides as autoimmune diseases antigenic probes. Chem. Today 2007; 25: 14-16.
8. Rose NR, Mackay IR. The Autoimmune Diseases. Elsevier: London, 2006.
9. Barakat S, Briand JP, Weber JC, van Regenmortel MH, Muller S. Recognition of synthetic peptides of Sm-D autoantigen by lupus sera. Clin. Exp. Immunol. 1990; 81: 256-262. (Pubitemid 20242531)
10. Sabbatini A, Bombardieri S, Migliorini P. Autoantibodies from patients with systemic lupus erythematosus bind a shared sequence of SmD and Epstein-Barr virus-encoded nuclear antigen EBNA I. Eur. J. Immunol. 1993; 23: 1146-1152. (Pubitemid 23120179)
11. Sabbatini A, Dolcher MP, Marchini B, Bombardieri S, Migliorini P. Mapping of epitopes on the SmD molecule: the use of multiple antigen peptides to measure autoantibodies in systemic lupus erythematosus. J. Rheumatol. 1993; 20: 1679-1683. (Pubitemid 24017569)
12. Riemekasten G, Marell J, Trebeljahr G, Klein R, Hausdorf G, Haupl T, Schneider-Mergener J, Burmester GR, Hiepe F. A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus. J. Clin. Invest. 1998; 102: 754-763. (Pubitemid 28399608)
13. Jaekel HP, Klopsch T, Benkenstein B, Grobe N, Baldauf A, Schoessler W, Werle E. Reactivities to the Sm autoantigenic complex and the synthetic SmD1-aa83-119 peptide in systemic lupus erythematosus and other autoimmune diseases. J. Autoimmun. 2001; 17: 347-354. (Pubitemid 34098419)
14. McClain MT, Ramsland PA, Kaufman KM, James JA. Anti-sm autoantibodies in systemic lupus target highly basic surface structures of complexed spliceosomal autoantigens. J. Immunol. 2002; 168: 2054-2062.
15. Brahms H, Meheus L, De Brabandere V, Fischer U, Luhrmann R. Symmetrical dimethylation of arginine residues in spliceosomal Sm protein B/B′ and the Sm-like protein LSm4, and their interaction with the SMN protein. RNA 2001; 7: 1531-1542. (Pubitemid 33078929)
16. Brahms H, Raymackers J, Union A, de Keyser F, Meheus L, Luhrmann R. The C-terminal RG dipeptide repeats of the spliceosomal Sm proteins D1 and D3 contain symmetrical dimethylarginines, which form a major B-cell epitope for anti-Sm autoantibodies. J. Biol. Chem. 2000; 275: 17122-17129. (Pubitemid 30398957)
17. Mahler M, Fritzler MJ, Bluthner M. Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies. Arthritis Res. Ther. 2005; 7: R19-R29.
18. Nienhuis RLF, Mandema E, Smids C. New serum factor in patients with rheumatoid arthritis: the antiperinuclear factor. Ann. Rheum. Dis. 1964; 23: 302-305.
19. Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ. Anti-keratin antibodies in rheumatoid arthritis. Br. Med. J. 1979; 2: 97-99.
20. Simon M, Girbal E, Sebbag M, Gomés-Daudrix V, Vincent C, Salema G, Serre G. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called 'antikeratin antibodies', autoantibodies specific for rheumatoid arthritis. J. Clin. Invest. 1993; 92: 1387-1393.
21. Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Durieux JJ, Serre G. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 1995; 95: 2672-2679.
22. Serre G. Autoantibodies to filaggrin/deiminated fibrin (AFA) are useful for the diagnosis and prognosis of rheumatoid arthritis, and are probably involved in the pathophysiology of the disease. Joint Bone Spine 2001; 68: 103-105. (Pubitemid 32275146)
23. Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, Simon M, Senshu T, Masson-Bessière C, Jolivet-Reynaud C, Jolivet M, Serre G. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J. Immunol. 1999; 162: 585-594. (Pubitemid 29018970)
24. Vossenaar ER, van Venrooij WJ. Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. Clin. Appl. Immunol. Rev. 2004; 4: 239-262. (Pubitemid 38495780)
25. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 1998; 101: 273-281.
26. Schellekens GA, Visser H, de Jong BAW, van den Hoogen FHJ, Hazes JMW, Breedveld FC, van Venrooij WJ. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000; 43: 155-163. (Pubitemid 30368225)
27. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, Serre G. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J. Immunol. 2001; 166: 4177-4184. (Pubitemid 32224951)
28. Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, van Venrooij WJ, Menard HA. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res. Ther. 2004; 6: R142-R150.
29. Pratesi F, Tommasi C, Anzilotti C, Chimenti D, Migliorini P. Deiminated Epstein Barr virus nuclear antigen I is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum. 2006; 54: 733-741.
30. Anzilotti C, Merlini G, Pratesi F, Tommasi C, Chimenti D, Migliorini P. Antibodies to a viral citrullinated peptide in rheumatoid arthritis. J. Rheumatol. 2006; 33: 647-651.
31. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002; 125: 2591-2625.
32. Mazzucco S, Matà S, Vergelli M, Fioresi R, Nardi E, Mazzanti B, Chelli M, Lolli F, Ginanneschi M, Pinto F, Massacesi L, Papini AM. A synthetic glycopeptide of human myelin oligodendrocyte glycoprotein to detect antibody response in multiple sclerosis and other neurological diseases. Bioorg. Med. Chem. Lett. 1999; 9: 167-172. (Pubitemid 29059521)
33. Carotenuto A, D'Ursi AM, Nardi E, Papini AM, Rovero P. Conformational analysis of a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope able to detect antibody response in multiple sclerosis. J. Med. Chem. 2001; 44: 2378-2381. (Pubitemid 32867408)
34. Papini AM, Rovero P, Chelli M, Lolli F. Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis. PCTWO03000733.
35. Papini AM. Simple test for multiple sclerosis. Nat. Med. 2005; 11: 13.
36. Lolli F, Mulinacci B, Carotenuto A, Bonetti B, Sabatino G, Mazzanti B, D'Ursi AM, Novellino E, Pazzagli M, Lovato L, Alcaro MC, Peroni E, Pozo-Carrero MC, Nuti F, Battistini L, Borsellino G, Chelli M, Rovero P, Papini AM. An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers ofmultiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 2005; 102: 10273-10278. (Pubitemid 41023362)
37. Lolli F, Mazzanti B, Pazzagli M, Peroni E, Alcaro MC, Sabatino G, Lanzillo R, Brescia Morra V, Santoro L, Gasperini C, Galgani S, D'Elios MM, Zipoli V, Sotgiu S, Pugliatti M, Rovero P, Chelli M, Papini AM. The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. J. Neuroimmunol. 2005; 167: 131-137. (Pubitemid 41242294)
38. Nuti F, Paolini I, Cardona F, Chelli M, Lolli F, Brandi A, Goti A, Rovero P, Papini AM. Fmoc-protected iminosugar modified asparagine derivatives as building blocks for glycomimetics-containing peptides. Bioorg. Med. Chem. 2007; 15: 3965-3973. (Pubitemid 46678853)
39. Ramirez-Alvarado M, Blanco FJ, Niemann H, Serrano L. Role of beta-turn residues in beta-hairpin formation and stability in designed peptides. J. Mol. Biol. 1997; 273: 898-912. (Pubitemid 27493727)
40. Carotenuto A, Alcaro MC, Saviello MR, Peroni E, Nuti F, Papini AM, Novellino E, Rovero P. Designed glycopeptides with different beta-turn types as synthetic probes for the detection of autoantibodies as biomarkers of multiple sclerosis. J. Med. Chem. 2008; 51: 5304-5309.
41. Real-Fernández F, Colson A, Bayardon J, Nuti F, Peroni E, Meunier-Prest R, Lolli F, Chelli M, Darcel C, Jugé S, Papini AM. Ferrocenyl glycopeptides as electrochemical probes to detect autoantibodies in multiple sclerosis patients' sera. Biopolymers 2008; 90: 488-495.